Get started
Author

Esther P. B. Rodman

Observed names: Esther B.P. Rodman, Esther P. Rodman, Esther P.B. Rodman, Esther Rodman
ORCID: 0000-0003-0903-8251
Observed ORCID: 0000-0003-0903-8251
OpenAlex ID: A5065291316
Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer
2022 · Kirsten G. M. Aspros, Jodi M. Carter, et al. · npj Breast Cancer · 19
PDF
Lestaurtinib’s antineoplastic activity converges on JAK/STAT signaling to inhibit treatment naïve and therapy resistant forms ovarian cancer
2025 · Esther P. B. Rodman, Michael J. Emch, et al. · npj Precision Oncology · 8
PDF
Disruption of estrogen receptor beta’s DNA binding domain impairs its tumor suppressive effects in triple negative breast cancer
2023 · Kirsten G. M. Aspros, Michael J. Emch, et al. · Frontiers in Medicine · 6
PDF
Nuclear GSK-3β and Oncogenic KRas Lead to the Retention of Pancreatic Ductal Progenitor Cells Phenotypically Similar to Those Seen in IPMN
2022 · Li Ding, Kaely Roeck, et al. · Frontiers in Cell and Developmental Biology · 5
Abstract 1129: Interrogating JAK/STAT signaling in ovarian cancer as a potential oncogenic driver and therapeutic target
2022 · Esther Rodman, Michael Emch, et al. · Cancer Research · 2
Novel (Z)-endoxifen-related new chemical entities exhibit potent anti-cancer activity in ERα+ breast cancer
2026 · Lena Batoon, Rajeev S. Muthyala, et al. · npj Breast Cancer
CTPS1 is an unexplored vulnerability in breast and ovarian cancer
2026 · Xiyin Wang, Michael J. Emch, et al. · Theranostics
PDF
BH3 mimetics as single agents and with endoxifen in ERα+ breast cancer models
2026 · Lena Batoon, Xiyin Wang, et al. · Research Square
PDF
Antibody-drug conjugates for advanced/recurrent high-grade endometrial cancer: potential targets, strategies and challenges
2026 · Yusuke Matoba, Esther Rodman, et al. · Research Square
PDF
STAT1 and STAT3 signaling in ovarian cancer: prognostic biomarkers and therapeutic targets
2026 · Esther P.B. Rodman, Aditya Bhagwate, et al. · BMC Cancer
Abstract 4560: CTPS1 as a metabolic vulnerability and novel therapeutic target in breast and ovarian cancer
2026 · Xiyin Wang, Michael Emch, et al. · Cancer Research
392 Mechanisms of resistance of STP938 in ovarian cancer
2026 · Hannah Smith, Xiyin Wang, et al. · Journal of Clinical and Translational Science
PDF
Abstract A064: Uncoupling CX3CL1-CX3CR1 Axis in IPMN Development Through Transgenic Mouse Models
2025 · Li Ding, Kaely Roeck, et al. · Cancer Research
Abstract PR005: Exploiting CTPS1 dependency for the treatment of ovarian cancer
2025 · Xiyin Wang, Michael J. Emch, et al. · Cancer Research
Abstract P3-02-22: The role of circular RNAs in triple-negative breast cancer and chemotherapy resistance
2025 · Xiyin Wang, Michael J. Emch, et al. · Clinical Cancer Research
Abstract 1666: Novel endoxifen-based proteolysis targeting chimera (PROTAC) small molecules synergize with olaparib and exhibit potent antitumor activity in triple negative breast cancer through induction of DNA damage
2025 · Aamod S. Dekhne, Swaathi Jayaraman, et al. · Cancer Research
Abstract 6388: Exploiting CTPS1 dependency for the treatment of breast and ovarian cancer
2025 · Xiyin Wang, Michael Emch, et al. · Cancer Research
Exploiting CTPS1 Dependency for the Treatment of Breast and Ovarian Cancer (Abstract ID: 159001)
2025 · Xiyin Wang, Michael J. Emch, et al. · Journal of Pharmacology and Experimental Therapeutics
Lestaurtinib’s antineoplastic activity converges on JAK/STAT signaling to inhibit advanced forms of therapy resistant ovarian cancer
2024 · Esther P.B. Rodman, Michael J. Emch, et al. · bioRxiv (Cold Spring Harbor Laboratory)
Abstract PO2-18-08: Identification of novel genetic/therapeutic vulnerabilities in breast cancer
2024 · Xiyin Wang, Michael Emch, et al. · Cancer Research
Abstract 1878: CTPS1: An unexplored vulnerability in breast and ovarian cancer
2024 · Xiyin Wang, Michael Emch, et al. · Cancer Research
Abstract 1224: 3D models of chemotherapy- and PARPi-resistant ovarian cancer indicate essential roles for JAK/STAT signaling in mediating drug resistance
2024 · Esther Rodman, Xiyin Wang, et al. · Cancer Research
Abstract B002: Exploiting JAK/STAT signaling to inhibit highly advanced and resistant forms of ovarian cancer
2024 · Esther Rodman, Michael Emch, et al. · Cancer Research
Abstract 4862: Investigation of the JAK/STAT signaling pathway in chemotherapy and PARP inhibitor resistant ovarian cancer
2023 · Esther Rodman, Michael Emch, et al. · Cancer Research
Nuclear GSK-3β and Oncogenic KRas Promote Expansion of Terminal Duct Cells and the Development of Intraductal Papillary Mucinous Neoplasm
2020 · Li Ding, Kaely Roeck, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Works count: 25
Citation count: 40
H-index: 4
I10-index: 1
Year
Topic
Type